Biodesix, Inc. (BDSX)
23.13
-1.58
(-6.39%)
USD |
NASDAQ |
Oct 16, 13:09
Biodesix Research and Development Expense (Quarterly) : 3.135M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.135M |
| March 31, 2026 | 3.285M |
| December 31, 2025 | 2.87M |
| September 30, 2025 | 2.992M |
| June 30, 2025 | 3.269M |
| March 31, 2025 | 2.87M |
| December 31, 2024 | 2.414M |
| September 30, 2024 | 2.547M |
| June 30, 2024 | 2.558M |
| March 31, 2024 | 2.04M |
| December 31, 2023 | 1.889M |
| September 30, 2023 | 1.938M |
| June 30, 2023 | 2.91M |
| March 31, 2023 | 3.251M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.565M |
| September 30, 2022 | 2.97M |
| June 30, 2022 | 3.361M |
| March 31, 2022 | 3.206M |
| December 31, 2021 | 2.852M |
| September 30, 2021 | 3.293M |
| June 30, 2021 | 3.323M |
| March 31, 2021 | 3.321M |
| December 31, 2020 | 3.105M |
| September 30, 2020 | 2.706M |
| June 30, 2020 | 2.107M |
| March 31, 2020 | 2.90M |
| December 31, 2019 | 2.502M |
| September 30, 2019 | 2.359M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Quest Diagnostics, Inc. | -- |
| Labcorp Holdings, Inc. | -- |
| OPKO Health, Inc. | 33.17M |
| Psychemedics Corp. | -- |
| NeoGenomics, Inc. | 10.76M |